GASTROESOPHAGEAL JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug MK-1200 tested in advanced cancer patients
Disease control CompletedThis study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThis pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Immunotherapy combo aims to boost stomach cancer survival after surgery
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Stomach cancer drug combo shows promise in new trial
Disease control CompletedThis study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Researchers analyze Nivolumab's Real-World impact on stomach cancer patients in china
Knowledge-focused CompletedThis study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in everyday practice and what treatment patterns were used. No …
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC